What Happened? Shares of animal health company Elanco (NYSE:ELAN) jumped 3% in the pre-market session after the company ...

A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in ...

The efficacy of ruxolitinib cream in pediatric patients shows that nonsteroidal management of atopic dermatitis is feasible, ...

In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented.

The combined company will operate under the name 'ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol ...

Oregon Health & Science University-led research is reporting that daily full-body emollient use starting before 9 weeks of ...

A real-world study on JAK inhibitors in atopic dermatitis reveals that while body weight has minimal impact on short-term ...

Almirall continues to invest in its leading R&D capabilities, aligning its pipeline with its long-term vision of leadership in medical dermatology. In H1 2025, R&D investment increased by ...

Elanco Animal Health said it has received marketing authorization for Zenrelia, a dermatology treatment for dogs, from the European Commission. The animal health products and services provider said ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

Food allergies in children are linked to higher risks for anxiety, depression, and eating disorders, with these risks differing from those seen in other chronic conditions.